论文部分内容阅读
目的:探讨肺癌食管癌缺失基因1（deleted in lung and esophageal cancer 1，DLEC1）对骨肉瘤细胞增殖和转移的影响及其机制。方法:16对骨肉瘤患者的癌组织和配对癌旁组织，比较其DLEC1免疫组织化学染色得分。以人骨肉瘤143B细胞系为研究对象，随机分为重组腺病毒DLEC1过表达载体（pDC316-DLEC1）转染组和对照载体（pDC316-Null）转染组。体外实验筛选稳定转染的细胞克隆，比较两组EdU阳性染色比例、细胞周期分布比例、凋亡细胞比例、Transwell迁移和侵袭细胞数量、钙黏蛋白E和波形蛋白表达量及NF-κB、AKT和ERK信号通路蛋白相对表达量的差异。体内实验构建骨肉瘤裸鼠皮下成瘤模型和尾静脉注射肺转移模型，比较两组皮下种植瘤肿瘤体积、肿瘤重量及肺转移结节数量的差异。结果:骨肉瘤癌组织和癌旁组织中DLEC1的免疫组织化学染色得分分别为（2.88±1.15）分和（4.25±1.06）分。pDC316-DLEC1组较pDC316-Null组，EdU阳性染色比例（36.47%±1.90%和51.47%±2.89%）和S期细胞比例（33.31%±0.61%和43.77%±1.47%）减少，而G0/G1期细胞比例（46.87%±0.73%和35.47%±1.14%）和凋亡细胞比例（13.83%±1.01%和3.30%±0.26%）增加。pDC316-DLEC1组的Transwell迁移细胞、侵袭细胞及波形蛋白的mRNA和蛋白相对表达量分别为（199.00±12.53）个、（104.67±9.07）个、0.59±0.02和0.54±0.08，均少于pDC316-Null组的（369.67±10.02）个、（299.67±12.06）个、1.00±0.02和1.00±0.00，而钙黏蛋白E的mRNA和蛋白相对表达量（2.40±0.05和1.98±0.10）均多于pDC316-Null组（1.00±0.02和1.00±0.00）。pDC316-DLEC1组中NF-κB（p65）、p-AKT（Ser473）和p-ERK（Thr202/Tyr204）的蛋白相对表达量分别较pDC316-Null组减少51.67%±4.04%、64.67%±5.51%和48.67%±4.73%。pDC316-DLEC1组较pDC316-Null组，皮下种植瘤肿瘤体积[（320.00±145.22）mmn 3和（798.00±221.94）mmn 3]、肿瘤重量[（0.49±0.17）g和（0.88±0.14）g]和肺转移结节数量[（7.71±1.80）个和（20.86±3.53）个]均减少。n 结论:DLEC1可抑制人骨肉瘤143B细胞系的NF-κB、AKT和ERK信号通路，并进一步通过诱导细胞周期阻滞和细胞凋亡抑制其增殖能力，同时通过逆转上皮间充质转化进程抑制其转移能力。“,”Objective:To explore the effects of deleted in lung and esophageal cancer 1 (DLEC1) on osteosarcoma cells and the underlying mechanism.Methods:Immunohistochemical staining for DLEC1 was scored in sixteen paired osteosarcoma tissues and adjacent normal tissues obtained. The present study was conducted on human osteosarcoma 143B cells which were randomly divided into two groups, pDC316-DLEC1 transfection group and pDC316-Null transfection group. Differences in the proportion of EdU-positive cells, cell cycle distribution, proportion of apoptosis cells, number of migrating and invasive cells, expression of epithelial-mesenchymal transformation (EMT) markers (E-cadherin and vimentin), relative protein expression levels of NF-κB, AKT and ERK signaling pathways were assessed between the pDC316-DLEC1 and pDC316-Null transfection groups in in vitro study. The subcutaneous inoculation model and tail vein injection model were developed to evaluate the differences in subcutaneous tumor volume, subcutaneous tumor weight and pulmonary tumor nodules between the above two groups in in vivo study.Results:The DLEC1 immunostaining scores for osteosarcoma tissues and adjacent normal tissues were 2.88±1.15 and 4.25±1.06, respectively. The proportions of EdU-positive cells (36.47%±1.90% n vs 51.47%±2.89%) and S phase cells (33.31%±0.61 n vs 43.77%±1.47%) were decreased, while G0/G1 phase cells (46.87%±0.73% n vs 35.47%±1.14%) and apoptotic cells (13.83%±1.01% n vs 3.30%±0.26%) were increased in the pDC316-DLEC1 transfection group compared to those in the pDC316-Null transfection group. Decreased number of migrating cells (199.00±12.53 n vs 369.67±10.02) and invasive cells (104.67±9.07 n vs 299.67±12.06) and relative expression of vimentin mRNA (0.59±0.02 n vs 1.00±0.02) and protein (0.54±0.08 n vs 1.00±0.00) were observed in the pDC316-DLEC1 transfection group, while relative expression of E-cadherin mRNA (2.40±0.05 n vs 1.00±0.02) and protein(1.98±0.10 n vs 1.00±0.00) in the pDC316-DLEC1 transfection group were higher than those in the pDC316-Null transfection group. The relative protein expression of NF-κB (p65), p-AKT (Ser473) and p-ERK (Thr202/Tyr204) in the pDC316-DLEC1 transfection group were decreased by 51.67%±4.04%, 64.67%±5.51% and 48.67%±4.73% compared to those in the pDC316-Null transfection group. In in vivo study, 143B cells in the pDC316-DLEC1 transfection group formed smaller (320.00±145.22 mmn 3vs 798.00±221.94 mmn 3) and lighter (0.49±0.17 g n vs 0.88±0.14 g) subcutaneous tumors and less metastatic lung nodules (7.71±1.80 n vs 20.86±3.53) compared with those in the pDC316-Null transfection group.n Conclusion:Overexpression of DLEC1 could suppress the NF-κB/AKT/ERK signaling pathways in 143B cells, which further induces G0/G1 arrest and apoptosis that ultimately inhibits cell proliferation and reduces the metastatic potential through reversing EMT.